Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Change in Accured Expenses (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Change in Accured Expenses for 17 consecutive years, with -$544000.0 as the latest value for Q1 2026.

  • Quarterly Change in Accured Expenses fell 54400100.0% to -$544000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$265497.0 through Jan 2026, down 380.82% year-over-year, with the annual reading at $1.3 million for FY2025, 589.99% up from the prior year.
  • Change in Accured Expenses for Q1 2026 was -$544000.0 at PharmaCyte Biotech, down from -$75000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $1.4 million in Q2 2025, with the low at -$1.0 million in Q3 2025.
  • Average Change in Accured Expenses over 5 years is $20881.1, with a median of $9013.0 recorded in 2024.
  • The sharpest move saw Change in Accured Expenses skyrocketed 2026.88% in 2022, then tumbled 54400100.0% in 2026.
  • Over 5 years, Change in Accured Expenses stood at -$80476.0 in 2022, then skyrocketed by 437.86% to $271896.0 in 2023, then plummeted by 96.69% to $9013.0 in 2024, then crashed by 932.13% to -$75000.0 in 2025, then tumbled by 625.33% to -$544000.0 in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$544000.0, -$75000.0, and -$1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.